ESMO 2025

Refining the standard treatments for early breast…

Toward a new standard - T-DXd in early breast cancer

Confirmative OS data on CDK4/6 inibitors for pts with…

Rethinking dosing in TNBC

T-DXd right from the start – in a neoadjuvant situation…

Optimal timepoint of G-CSF administration after…

Financial toxicity

T-DXd in high-risk patients in the postneoadjuvant…

Individual consultation remains important

T-DXd neoadjuvant improves pCR

OS-benefit with abemaciclib

POSITIVE trial - update

Ki67 after preoperative chemotherapy - a new strong…

Adjuvant data with CDK4/6 inhibitors in HR+ breast…

A first step into a great story

First time OS - confirming clinical practice

CDK4/6 inhibitors – confirmed effect

The first neoadjuvant therapy decreases chemotherapy in…

monarchE OS

Optimizing G-CSF administration helps reducing side…

Great update for young women

New insights into PROTAC SERD vepdegestrant

Exciting news for young patients who want to get…

Momento óptimo para la administración de G-CSF después…

monarchE OS

Prima valutazione della OS: conferma della pratica…

Ki67 po przedoperacyjnej chemioterapii - nowy istotny…

Studio POSITIVE - aggiornamento

La primera terapia neoadyuvante reduce la quimioterapia…

Future perspectives on TNBC therapy

Future perspectives for firstline therapy

ADCs in mBC - the story is not finished

ADCs are coming for first line TNBC

ADC, the first

Stronger together

TROP2 number 3

Early positioning of third-generation ADCs in treatment

Meeting the unmet need in advanced TNBC not eligible…

TROP2 ADC, the second

Changing the paradigm of treatment in 1L of TNBC

Should this drug be available outside of China?

Reforming destiny

Gedatolisib in patients with PI3K wild type HR+ mBC

Survival data from SONIA

Combination matters

Breakthroughs for high-risk patients

Which ADC in 1L for metastatic TNBC

Another good option for patients with mTNBC

Gedatolisib in pazienti con mBC HR+ PI3K wild type

Nowa szansa dla chorych na zaawansowanego, potrójnie…

Gli ADC si fanno strada nella prima linea del TNBC

Otra buena opción para pacientes con mTNBC

Cambiando el paradigma del tratamiento en la primera…

Positionnement plus précoce des ADCs de troisième…

La combinazione conta

Più forti insieme

Immunotherapy and biomarkers in resectable NSCLC:…

Navigating ALK TKI choices in ALK+ NSCLC

A bridge to surgery

New chances for locally advanced NSCLC

NorthStar: Osimertinib ± local therapy in EGFR-mutant…

Therapy sequencing after EGFR-TKI progression: insights…

FLAURA2: OS outcomes in poor-prognosis EGFRm NSCLC with…

New targeted therapies in HER2-mutated NSCLC

Save and effective - Ivonescimab in HARMONi-6

Alectinib remains a potential SOC

HER2 altered - small population, many options

New options after EGFR-TKI failure

New treatment options for HER2-mutation positive NSCLC

The return of antiangiogenic strategy in squamous NSCLC

Sac-TMT - a potential new option for EGFRm NSCLC…

Ivonescimab in NSCLC - a new SOC?

New prospect for squamous tumors

Treat your BRAF-patients in 1L

ALK - longterm

sac-TMT a new SOC

Update for pts with BRAF mutation

Anti-TROP-2 ADCS - new data in EGFRm NSCLC

Local ablative therapy in EGFR-mutated NSCLC

Two frontline HER2-options - is this the future?

Sac-TMT now also available for NSCLC

EGFR exon 20 - What does the future hold?

Local therapy in addition to osimertinib 1st line in…

Is chemo-IO an option if you want a rapid response in…

NorthStar - new navigation principle

Two is better than one

Is this the end for pembrolizumab?

The added value of radiotherapy in EGFR mutated NSCLC

New kid on the block for EGFRm

Eradication of all disease - is this the true north?

New kid on the block for EGFRm

Sac - TMT - une nouvelle option potentielle pour le…

De toegevoegde waarde van radiotherapie bij…

Nuevas perspectivas para los tumores escamosos

È la fine per Pembrolizumab?

Le retour de la stratégie antiangiogénique dans le…

ADCS anti-TROP-2 - nouvelles données sur le EGFRm NSCLC

Prognostic role of exosomes in stage IIIA(N2) NSCLC…

Molecular factors and ctDNA dynamics linked to outcomes…

Tarlatamab combination in 1st line SCLC

Will tarlatamab improve 1st line treatment for…

DLL3 targeting drugs moving to frontline therapy

T-cell engager in 1st line SCLC

Bending the gravity of SCLC

Amélioration spectaculaire de la survie sans…

Doblando la gravedad del SCLC

A new class of drugs in Mesothelioma treatment

Another part of the puzzle

A step in the right direction

Kidney cancer advances from ESMO

Adjuvans in high risk RCC after surgery

Relevance of CPI neoadjuvant and adjuvant

Therapy-relevant aspects for first-line treatment of…

Input for the second line in ccRCC

Further intensification of therapy with potential…

More evidence in second-line treatment for metastatic…

The dawn of molecular imaging in renal cell carcinoma

MIBC: Is ctDNA monitoring ready for daily practice?

UTUC: Impressive PFS und OS Benefit with Disitamab…

NMIBC: Making the right choice for high risk patients!

Neoadjuvant combination of local and systemic therapy…

De-escalation promotes a better QoL while maintaining…

Perioperative and adjuvant standards for MIBC

Setting the bar even higher in MIBC

A highly selective FGFR3 inhibitor for first-line…

The ADC story continues

A newcomer in advanced urothelial cancer

A well-tolerated and effective new neoadjuvant concept…

When precision matters, the case of ctDNA in MIBC

Negative, but important data to discuss

New options for neoadjuvant therapy in MIBC

Dose modifications, new combinations, new substances in…

Therapy intensification in patients ineligible for…

New benchmark for MIBC and platinum-unsuitable patients

Neoadjuvant HER2-targeted therapy for kidney-sparing…

Is ICI to BCG suitable for NMIBC?

Too early for primetime

Adding checkpoint inhibitor in high risk NMIBC shows…

Better QoL for patients with metastatic bladder cancer

ADC Enfortumab vedotin + Pembrolizumab in MIBC

Un recién llegado en el cáncer urotelial avanzado

Cuando la precisión importa: el caso de ctDNA en MIBC

Elevando aún más el estándar en MIBC

Κύρια σημεία για τον καρκίνο της ουροδόχου κύστης από…

Is this the new standard of care?

Changed chemo-regimen leads to less toxicity in mHSPC

PSMAddition - Is it time for more?

The role of lutetium in mHSPC – is its use clinically…

Triplet regimen with reduced chemotherapy – fewer side…

Practice-changing data for mHSPC

New docetaxel regimen in combination with darolutamide…

Final OS results for EMBARK

OS-benefit in BCR

Example for biomarker guided precision medicine in…

Impressive OS-data from EMBARK

Ändrad kemoterapiregim leder till mindre toxicitet vid…

Imponerande OS-data från EMBARK

Thymic tumors - heads up